Aviva Ventures, Aviva plc's venture capital arm, has invested in Owlstone Medical Ltd, a medical diagnostics company developing a breathalyser that can detect diseases at a very early stage.
The company is currently developing tests for lung and colorectal cancer, two of the most common terminal cancer conditions worldwide. Aviva Ventures' investment takes Owlstone Medical's total funding to $23.5 million USD (£19.3 million GBP) since its spin out of Owlstone Inc in 2016. Aviva Ventures provides early stage investment to back entrepreneurs with high growth businesses and, over time, expects to have a portfolio of small investments in a number of companies which have significant...
Retains platform and financial advice business
Bedford-based mutual society chooses Disability Rights UK as its charity partner for 2018
Insurers should leave funeral planning to the experts, says Avalon CEO Paul Wilson
Financial wellbeing firm Neyber suggests better use of employee assistance programmes (EAPs) would benefit both workers and companies